Inscription à l’infolettre

Publications

Publications récentes

Voir les publications précédentes
  • 22 mai 2025

    Endothelial extracellular vesicle miR-423-5p regulates microvascular homeostasis and renal function after ischemia-reperfusion injury.

    Migneault F, Kim H, Doreille A, Lan S, Gendron A, Normand MH, Rimbaud AK, Dupont M, Bourdeau I, Bonneil E, Turgeon J, Dussault S, Thibault P, Dieudé M, Boilard E, Rivard A, Cardinal H, Hébert MJ
    JCI Insight 2025-05-22 ;10( 10 ):

  • 20 mai 2025

    Allogeneic Hematopoietic Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center.

    Castonguay M, Roy J, Claveau JS, Lachance S, Delisle JS, Kiss T, Cohen S, Fleury I, Mollica L, Ahmad I, Bambace N, Bernard L, Roy DC, Sauvageau G, Veilleux O
    Curr Oncol 2025-05-20 ;32( 5 ):

  • 19 mai 2025

    A Digital Microfluidic Platform for the Microscale Production of Functional Immune Cell Therapies.

    Little SR, Rahbari N, Hajiaghayi M, Gholizadeh F, Cloarec-Ung FM, Phillips J, Sinha H, Hirukawa A, Knapp D, Darlington PJ, Shih SCC
    Anal Chem 2025-05-19 ;97( 21 ):11026-11034

  • 7 mai 2025

    Blocking a key node in cancer signalling unlocks therapeutic potential.

    Lavoie H, Therrien M
    Nature 2025-05-07 ;

  • 28 avril 2025

    14-3-3ζ allows for adipogenesis by modulating chromatin accessibility during the early stages of adipocyte differentiation.

    Rial SA, You Z, Vivoli A, Paré F, Sean D, AlKhoury A, Lavoie G, Civelek M, Martinez-Sanchez A, Roux PP, Durcan TM, Lim GE
    Mol Metab 2025-04-28 ;97:102159

  • 28 avril 2025

    DDB1 engagement defines the selectivity of S656 analogs for cyclin K degradation over CDK inhibition.

    Moison C, Mendoza-Sanchez R, Gracias D, Schuetz DA, Spinella JF, Girard S, Thavonekham B, Chagraoui J, Durand A, Fortier S, MacRae T, Bonneil E, Rose Y, Mayotte N, Boivin I, Thibault P, Hébert J, Ruel R, Marinier A, Sauvageau G
    EMBO Rep 2025-04-28 ;

  • 20 avril 2025

    MARC, a novel modular chimeric antigen receptor, improves T cell-based cancer immunotherapies by preventing early T cell exhaustion and enhancing persistence.

    Tual M, Bellemare-Pelletier A, Moore S, Guipouy D, Farzam-Kia N, Jafarzadeh L, Quenneville J, Barrette B, Saba-El-Leil MK, Delisle JS, Gagnon E
    J Immunother Cancer 2025-04-20 ;13( 4 ):

  • 14 avril 2025

    IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia.

    Métois A, Bordeleau ME, Theret L, Hajmirza A, Moujaber O, Spinella JF, Chagraoui J, Mayotte N, Boivin I, Audemard E, Aubert L, Lisi V, Khakipoor B, Farah A, Bonneil E, Robert A, Lippens J, Moraitis A, Béliveau F, Feghaly A, Boucher G, Marcotte R, Gendron P, Thibault P, Lemieux S, Richard-Carpentier G, Lavallée VP, Hébert J, Roux PP, Sauvageau G
    Biomark Res 2025-04-14 ;13( 1 ):61

Voir plus de publications